Amarin Posts First Profit in Over Two Years as Expenses Fall 44%
AMRN is trading near its 52-week low of $11.25 (6.2% above the low).
Summary
Amarin reported Q3 2026 net income of $0.245 million, its first profitable quarter in over two years, versus a $7.7 million loss a year ago. Operating expenses fell 44% to $18.5 million after the $70 million cost-savings program wrapped up, and cash plus short-term investments rose to $323.4 million with no debt. Revenue still shrank 20% to $39.6 million as U.S. VASCEPA sales dropped 30% on generic pricing pressure, though the company held 47% of the U.S. IPE market. The growth story is international: European in-market demand rose an estimated 68% and global partner demand 55%, with licensing and royalty revenue up 139% to $2.7 million. Management said it continues working with Barclays, its exclusive financial advisor, on strategic alternatives — the key swing factor for a company this small. Q4 guidance calls for further expense reductions and positive operating cash flow.
At the time of this announcement, AMRN was trading at $11.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $252.4M. The 52-week trading range was $11.25 to $20.57. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.